Kim R. Tsuchimoto - 31 Mar 2022 Form 4 Insider Report for Monopar Therapeutics (MNPR)

Role
Chief Financial Officer
Signature
/s/ Kim R. Tsuchimoto
Issuer symbol
MNPR
Transactions as of
31 Mar 2022
Net transactions value
-$1,275
Form type
4
Filing time
01 Apr 2022, 17:28:25 UTC
Previous filing
04 Feb 2022
Next filing
01 Jul 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MNPR Common Stock Options Exercise +1,221 +25% 6,136 31 Mar 2022 Direct F1
transaction MNPR Common Stock Tax liability $1,275 -500 -8.1% $2.55 5,636 31 Mar 2022 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MNPR Restricted Stock Units Options Exercise $0 -1,221 -1.6% $0.000000 77,424 31 Mar 2022 Common Stock 1,221 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares acquired on vesting and settlement of restricted stock units.
F2 On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.